MDCO
The Medicines Company
The Medicines Company historical holders
total: 2
Ancient Art (Teton Capital) The Medicines Company transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2019 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2019 Q2
Quincy Lee has been an institutional investor in The Medicines Company (MDCO) since 2019 Q1. According to 2026 Q1 report, Quincy Lee doesn't hold any shares. The fund/company first acquired MDCO in 2019 Q1, initially purchasing 27,520 shares. Since the initial investment, Ancient Art (Teton Capital) has made 1 more transaction in this position.
When did Quincy Lee exit their MDCO position?
Quincy Lee no longer holds The Medicines Company (MDCO). They sold off their entire position in 2019 Q2, closing out an investment that began in 2019 Q1.
When did Quincy Lee first invest in MDCO?
Quincy Lee first invested in The Medicines Company (MDCO) in 2019 Q1 at the reported quarter-end price of $27.94 per share, acquiring 27,520 shares in their initial purchase.
What is Quincy Lee's average cost basis for MDCO?
Based on historical transaction data, Quincy Lee's estimated cost basis for The Medicines Company (MDCO) is approximately $27.94 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $27.94
- Weighted AVG sell price:
- $27.94
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.